Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
De-escalated PTCy and Ruxolitinib for GVHD Prophylaxis in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT
NCT05622318Phase 2Active, not recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Aug 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib and cyclophosphamide in graft-versus-host disease (GVHD), sponsored by Medical College of Wisconsin. Primary endpoint: Graft-Versus-Host Disease-Free Survival at 1 year. Started Aug 2023; status: active, not recruiting.
02
Drugs
ruxolitinibcyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05622318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05622318.